Treatment of IgA Nephropathy: A Rapidly Evolving Field.

The treatment landscape for IgA nephropathy is evolving rapidly, with goal-directed supportive care plus SGLT2 inhibitors and sparsentan now integral, and immunosuppression reserved for higher-risk patients identified by clinical and histologic parameters.